Tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for weight management, is a dual GIP and GLP-1 receptor agonist that has transformed metabolic disease treatment
Zepbound Switching: How to Transition From or To Other GLP-1/GIP Drugs Safely Zepbound Switching: How to Transition From or To Other Drugs in Class At a glance Drug / Zepbound (tirzepatide), Eli Lilly Drug class / Dual GIP and GLP-1 receptor agonist Approved indication / Chronic weight management in adults with BMI 30, or 27 with one weight-related comorbidity Dosing frequency / Once weekly subcutaneous injection Starting dose / 2.5 mg weekly, escalated every 4 weeks Maximum dose / 15 mg weekly Key trial / SURMOUNT-1 (N=2,539): 20.9% mean body-weight loss at 72 weeks on 15 mg Half-life / Approximately 5 days (supports once-weekly dosing) Common switch scenarios / Semaglutide to tirzepatide, liraglutide to tirzepatide, tirzepatide to oral semaglutide FDA approval date / November 8, 2023 (weight management indication) How Zepbound Works: Mechanism at the Receptor Level Zepbound binds both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor
10.1038/nrn2286 Nat
Shellfish anaphylaxis stands as the leading cause of food-related fatalities in Australia, as reported by the Australian Bureau of Statistics, and has exhibited a concerning increase over the past decades [34, 35]
If youre experiencing persistent fatigue, low energy, or brain fog that doesnt improve with rest, you might be dealing with a Vitamin B12 deficiency
